TheREx team - Experimental Recombinant Therapy - is organized along the following lines:
rational design of therapeutic proteins and vectors
interactions host-pathogen and molecular bases of chronic granulomatous disease
hematopoietic stem cells and myelodysplasia.
These complementary therapeutic approaches are reinforced by capacities in preformulation and formulation and by a plateforme for precocious phase clinical trials in oncology and hematology.
Our approaches in the field of ‘health technologies’ allow the development of innovative therapy in enzymopathies, hemopathies, and anti-tumor or anti-infectious immunotherapy.
The knowhow of the team is valorized through two startups:
SYNTHELIS: production of membrane proteins
APCure: bacterial vectors for immunotherapy